The Beatrice Hunter Cancer Research Institute logo
  • Dr. Murali (Mal) Rajaraman, MD, FRCPC


Associate Professor, Department of Radiation Oncology
Radiation Oncologist, QEII Cancer Care Program


Dalhousie University Faculty of Medicine, Capital Health, Nova Scotia Health Authority

Research Interests:

Dr. Rajaraman’s clinical expertise is in the areas of Thyroid Cancer, Head & Neck Cancer, Breast Cancer, Sarcoma, Lung Cancer, and Skin Cancer. Research activities and interests are in the fields of Neosis, Clinical and Research Databases, Thyroid Cancer, PET/CT scan utilization in Oncology and clinical trials. Administrative and academic responsibilities have included Director of the Dalhousie University Radiation Oncology Residency Training Program as well as membership of the NCIC-CTG Canadian Sarcoma Group Executive Committee, CARO Manpower and Standards Committee, CARO Elekta Research Fellowship Program Selection Committee, Chairmanships of the Cancer Care Nova Scotia Cancer Site Teams in Head and Neck Cancer and Sarcoma (Musculoskeletal Cancer), Thyroid Cancer Canada Medical Advisory Panel, and Associate Member of the Beatrice Hunter Cancer Research Institute (BHCRI).

Thyroid and Head & Neck Cancer Collaborative Multicentre Studies to Improve Patient Outcomes

Dr. Rajaraman is co-chair of the Canadian Network for Cancer of the Thyroid (CANNECT) which is a collaborative network of researchers and clinicians committed to improving patient care, research and advocacy of thyroid cancer across Canada.  This currently involves 10 centres in 7 provinces.  The group has published several abstracts and papers using Canadian treatment specific outcome data on thyroid cancer.  Ongoing work involves the establishment of a National Tumour Board to aid in management of difficult thyroid cancer cases.  Dr. Rajaraman is also involved in multicenter, collaborative studies on head and neck cancer.

Involvement with BHCRI to date:

Dr. Murali Rajaraman is an Associate Member


902 473 6018



Dickson Building, QEII Health Sciences Centre, 5820 University Avenue, Halifax, NS, B3H1V7


Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010, I. Rachinsky, M. Rajaraman, W. D. Leslie, A. Zahedi, C. Jefford, A. McGibbon, J. E. M. Young, K. A. Pathak, M. Badreddine, S. De Brabandere, H. Fong, and S. Van Uum Volume 2016 (2016), Article ID 2867916, 9 pages

Davis, CA, Thomas C, Abdolell M, Day Allan, Hollenhorst H, Rajaraman M, Mulroy L, Bowes, D, Cwajna, S, Rheaume D, Patil N, Burrell S, Wilke D.  Investigating the impact of positron emission tomography-computed tomography versus computed tomography alone for high-risk volume selection in head and neck and lung patients undergoing radiotherapy: Interim findings.  J Med Imaging and Rad Sciences 2015;46:148-155

Siu S, McDonald JT, Rajaraman M, Franklin JH, Paul T, Rachinsky I, Morrison D, Imran SA, Burrell S, Hart RD, Driedger A, Badreddine M, Yoo J, Corsten M, Van Uum SH. Is lower socioeconomic status associated with more advanced thyroid cancer stage at presentation? A study in two Canadian centers. Thyroid 2014: 24(3):545-51

Site by: Spectacle Group